Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Novartis To Cut 8,000 Jobs In Global Restructure
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.
Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.
Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
Eiger Expects To Join Gilead In Future Multi-Billion Dollar Hepatitis D Market
The little-known company could be set for a transformational year, with a Phase III readout in hepatitis D and a filing for a promising COVID-19 candidate.